Baricitinib NCT07262983 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Recruiting

Recruitment status

20

Planned enrollment

2030-05-01

Primary-completion proxy

Executive view

NCT07262983 evaluates Baricitinib in Job Syndrome. The disclosed sponsor is National Institute of Allergy & Infectious Diseases, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Incidence of SAEs, AEs requiring study drug discontinuation., assessed over Through end of study.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07262983 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Job Syndrome landscape. Drug & Asset MCP drug_fetch was queried for Baricitinib, while Company & Deal Intelligence MCP organization_fetch was queried for National Institute of Allergy & Infectious Diseases.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07262983	Baricitinib	Phase 1 / Recruiting	National Institute of Allergy & Infectious Diseases	United States	Incidence of SAEs, AEs requiring study drug discontinuation. Through end of study	2030-05-01
NCT07331467	MC150	Phase 1 / Recruiting	Chongqing Precision Biotechnology Co., Ltd.	China	The safety of CAR-T cell therapy in patients with refractory SLE [Safety] 3 months	2026-07-01
NCT07332481	Enpatoran	Phase 3 / Recruiting	EMD Serono Research & Development Institute, Inc.	Romania, United States, Japan, Switzerland, Spain, South Korea, Taiwan Province, Poland, Italy, Slovakia, Israel, France, Bulgaria, Germany	Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defi… At Week 24	2029-05-24
NCT07333118	GT801	Early Phase 1 / Recruiting	Zhuhai Grit Biotechnology Co., Ltd.	China	Proportion of participants experiencing dose limiting toxicity 28 days post GT801 infusion	2028-03-31
NCT07328581	BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics)	Phase 2 / Recruiting	iCell Gene Therapeutics, Inc.	United States	Number of Adverse Events after ICG318 infusion Starting day 0 and up to 1 year after ICG318 infusion.	2028-12-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07262983 is a Phase 1, recruiting study with 20 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Incidence of SAEs, AEs requiring study drug discontinuation.” over “Through end of study.” The retrieved endpoint description is: To determine the safety and tolerability of JAK inhibitor treatment (baricitinib) in patients with Job s syndrome with lupus-like disease and/or AD..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 20 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Job Syndrome. These records do not establish direct evidence for NCT07262983 unless the registration number matches.

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF 06823859 IN A…

Phase 2; n=8; Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12(Least Squares Mean): Least Square Mean Difference = 0.5(90% CI, -3.7 to 4.6), P-Value = 0.8243; Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12(Least Squares Mean): Least Square Mean Difference = 0.5(90% CI, -3.7 to 4.6), P-Value = 0.8243 Source: https://clinicaltrials.gov/ct2/show/results/NCT05879718

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

Phase 2; n=149; Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28 = 10 Participants ; Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28 = 15 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT06161116

Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial

Phase 2; n=79; eGFR = -2.0 ml/min/1.73 m2 Source: https://pubmed.ncbi.nlm.nih.gov/42549085/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Baricitinib is indexed as Small molecule drug with JAK1 x JAK2 biology and a global stage of Approved. The asset profile lists Incyte Corp. as an originator or developer.

National Institute of Allergy & Infectious Diseases is indexed in United States with the website http://www3.niaid.nih.gov. Operates as an agency of the United States department of health and human services The record lists 89 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Baricitinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07262983
Protocol source: https://clinicaltrials.gov/study/NCT07262983
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.

Baricitinib in Job Syndrome is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of SAEs, AEs requiring study drug discontinuation. and 2030-05-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP